WHY IT MATTERS: If oral thin film cannabinoid delivery becomes clinically available, patients who struggle with inconsistent edible absorption or who cannot inhale may gain access to a faster-acting, more precisely dosed alternative. CLINICAL OVERVIEW: Oral thin film delivery systems for cannabinoids represent an evolving area of drug delivery research that could address some of the longstanding challenges in cannabis medicine, including inconsistent absorption, delayed onset, and difficulty achieving precise dosing. From a clinical perspective, sublingual and buccal delivery methods bypass first-pass hepatic metabolism, potentially offering more predictable pharmacokinetics compared to traditional edibles while providing a smoke-free alternative for patients who need rapid onset without inhalation.